Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

Blood

Volumn 117, Issue 26, 2011, Pages 7007-7013

  Buyse, Marc ^a,b   Squifflet, Pierre ^a   Lange, Beverly J ^c   Alonzo, Todd A ^d   Larson, Richard A ^e   Kolitz, Jonathan E ^f   George, Stephen L ^g   Bloomfield, Clara D ^h   Castaigne, Sylvie ⁱ   Chevret, Sylvie ^j   Blaise, Didier ^k   Maraninchi, Dominique ^k   Lucchesi, Kathryn J ^l   Burzykowski, Tomasz ^a,b  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ CENTRE HOSPITALIER DE VERSAILLES   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l MedVal Scientific Information Services   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

EID: 79959845267     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-337725     Document Type: Article

References (50)

1. Rowe JM, Xiaochun L, Cassileth PA, et al. Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group experience [abstract]. Blood. 2005;106(11):546.
2. Romero AI, Thoren FB, Aurelius J, et al. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol. 2009;70(3):194-205.
3. Krug U, Lubbert M, Buchner T. Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? Curr Opin Hematol. 2010;17(2):85-90.
4. Blaise D, Olive D, Michallet M, et al. Impairment of leukaemia-free survival by addition of interleukin- 2-receptor antibody to standard graft-versus-host prophylaxis. Lancet. 1995;345(8958):1144-1146.
5. Lowdell MW, Koh MB. Immunotherapy of AML: future directions. J Clin Pathol. 2000;53(1):49-54. (Pubitemid 30039386)
6. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332(4):217-223.
7. Malkovský M, Sondel PM. Interleukin 2 and its receptor: structure, function and therapeutic potential. Blood Rev. 1987;1(4):254-266.
8. Stoppa AM, Fossat C, Blaise D, et al. Interleukin- 2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. Eur Cytokine Netw. 1991;2(4):231-237.
9. Adler A, Albo V, Blatt J, Whiteside TL, Herberman RB. Interleukin-2 induction of lymphokine- activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission. Blood. 1989;74(5):1690-1697. (Pubitemid 19251547)
10. Lauria F, Raspadori D, Rondelli D, Ventura MA, Foa R. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia. 1994;8(5):724-728.
11. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia. 1996;10(3):478-482. (Pubitemid 26128788)
12. Macdonald D, Jiang YZ, Gordon AA, et al. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leuk Res. 1990;14(11-12):967-973.
13. Blaise D, Attal M, Pico JL, et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma. 1997; 25(5-6):469-478. (Pubitemid 27361892)
14. Maraninchi D, Blaise D, Viens P, et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood. 1991;78(9):2182-2187.
15. Maraninchi D, Vey N, Viens P, et al. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma. 1998;31(3-4):343-349. (Pubitemid 29033955)
16. Farag SS, George SL, Lee EJ, et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B Study 9420. Clin Cancer Res. 2002;8(9): 2812-2819. (Pubitemid 35025724)
17. Cortes JE, Kantarjian HM, O'Brien S, et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 1999;85(7):1506-1513. (Pubitemid 29152822)
18. Stein AS, O'Donnell MR, Slovak ML, et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J Clin Oncol. 2003;21(4):615-623. (Pubitemid 46621894)
19. Ganser A, Heil G, Seipelt G, et al. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML). Ann Hematol. 2000;79(1):30-35. (Pubitemid 30157747)
20. Blaise D, Attal M, Reiffers J, et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw. 2000;11(1):91-98.
21. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 Study. J Clin Oncol. 2010;28(5):808-814.
22. Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008;26(30):4934-4939.
23. Kolitz JE, Hars V, DeAngelo DJ, et al. Phase III trial of immunotherapy with recombinant interleukin- 2 (rIL-2) versus observation in patients <60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808 [abstract]. Blood. 2007;110(11):157.
24. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2008;111(3):1044- 1053. (Pubitemid 351213382)
25. Willemze R, Suciu S, Mandelli F, et al. Value of low dose IL-2 as maintenance following consolidation treatment or autologous transplantation in acute myelogenous leukemia (AML) patients aged 15-60 years who reached CR after high dose (HD-AraC) vs standard dose (SD-AraC) cytosine arabinoside during induction: results of the AML-12 trial of EORTC and GIMEMA Leukemia Groups [abstract]. Blood. 2009;114(22):791.
26. Meloni G, Vignetti M, Pogliani E, et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am. 1997;3(suppl 1):S43-S47.
27. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108(1):88-96. (Pubitemid 43996626)
28. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115(3):453-474.
29. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F, eds. Methods for Meta-Analysis in Medical Research. Chichester, United Kingdom: John Wiley & Sons; 2000.
30. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
31. Farag SS, Ruppert AS, Mrozek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(3):482-493. (Pubitemid 46224225)
32. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intentionto- treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232-1240. (Pubitemid 36988027)
33. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
34. Burnett AK. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? An adult treater's view. Br J Haematol. 2002;118(2):357-364. (Pubitemid 34994636)
35. Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia? Lancet. 1984; 2(8393):28-30.
36. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041-2050.
37. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2(8552):175-178. (Pubitemid 17091848)
38. Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol. 1996;57(4): 312-319. (Pubitemid 26413125)
39. Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol. 1996; 92(3):620-626. (Pubitemid 26078021)
40. Lotzová E, Savary CA, Herberman RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol. 1987; 138(8):2718-2727. (Pubitemid 17051855)
41. Bertheas MF, Maraninchi D, Lafage M, et al. Partial chimerism after T-cell-depleted allogeneic bone marrow transplantation in leukemic HLA-matched patients: a cytogenetic documentation. Blood. 1988;72(1):89-93.
42. Hellstrand K. Histamine in cancer immunotherapy: a preclinical background. Semin Oncol. 2002;29(3 suppl 7):35-40. (Pubitemid 34620434)
43. Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999;48(7):353-362. (Pubitemid 29461387)
44. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother. 1999;48(7):346-352. (Pubitemid 29461386)
45. Hellstrand K, Brune M, Dahlgren C, et al. Alleviating oxidative stress in cancer immunotherapy: a role for histamine? Med Oncol. 2000;17(4):258-269.
46. Hansson M, Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of NK-cells: protection against monocyte-induced apoptosis. Scand J Immunol. 1996;44(2):193-196. (Pubitemid 26246740)
47. Hansson M, Hermodsson S, Brune M, et al. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res. 1999;19(10):1135-1144. (Pubitemid 29502780)
48. Betten A, Bylund J, Christophe T, et al. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. J Clin Invest. 2001;108(8): 1221-1228. (Pubitemid 32995381)
49. Berry SM, Broglio KR, Berry DA. Incremental benefit of histamine dihydrochloride when added to interleukin-2 for remission maintenance in acute myeloid leukemia: a Bayesian meta-analysis [abstract]. Blood. 2010;116(21):2182.
50. Hellstrand K, Mellqvist UH, Wallhult E, et al. Histamine and interleukin-2 in acute myelogenous leukemia. Leuk Lymphoma. 1997;27(5-6):429- 438. (Pubitemid 28029904)